OM
Outset Medical
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
stock price surged significantly
EPS Beats Expectation
Dark Cloud Cover
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About OM
Outset Medical, Inc.
A medical technology company that develops Tablo Hemodialysis System for kidney patients and health care providers
Healthcare Equipment and Supplies
05/05/2003
09/15/2020
NASDAQ Stock Exchange
354
12-31
Common stock
3052 Orchard Dr., San Jose, California 95134
--
Outset Medical, Inc., was originally incorporated in Delaware on May 5, 2003 under the name Home Dialysis Plus, Ltd. The company name was changed to Outset Medical, Inc. on January 5, 2015. The company is a fast-growing medical technology company that is the first to adopt similar technologies to reduce the cost and complexity of dialysis. The company believes that the Tablo Hemodialysis System (Tablo) represents a major technological advance that enables novel and transformative dialysis care in acute and home settings. The company has designed Tablo from the outset as a single enterprise solution that can be used throughout the care process, allowing anyone to undergo dialysis anytime, anywhere.
Company Financials
EPS
OM has released its 2024 Q4 earnings. EPS was reported at -0.37, versus the expected -0.41, beating expectations. The chart below visualizes how OM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
OM has released its 2024 Q4 earnings report, with revenue of 29.47M, reflecting a YoY change of -3.41%, and net profit of -25.64M, showing a YoY change of 33.58%. The Sankey diagram below clearly presents OM’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
